targeted-drug-delivery
(3)
The hardest part of gene editing is getting there
A Berkeley-born biotech wants to make genetic medicine travel without a viral vector or lipid nanoparticle. Its miniproteins are an elegant delivery idea; the harder test is now scientific and financial.
Callio Put Two Cancer Drugs on One Guided Missile
Most antibody-drug conjugates carry one weapon. Callio is testing whether two coordinated payloads on the same HER2-targeted carrier can make resistant tumors run out of exits.
Theradaptive
Theradaptive is a clinical-stage biotech in Frederick, Maryland that re-engineers therapeutic proteins so they bind to materials and stay exactly where a surgeon places them. Its lead protein, AMP2, is a material-binding variant of the bone-growth protein rhBMP-2; combined with an implantable scaffold it becomes OsteoAdapt, a regenerative product being tested in spinal fusion, dental, and orthopedic procedures. Founded by MIT-trained Army veteran Luis Alvarez after seeing battlefield injuries, the company aims to make biologics safer by keeping them on-target.